Latest On Basilea Pharmaceutica AG (BPMUF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-14 18:05 EST | News | Basilea Pharmaceutica AG (BPMUF) Q4 2022 Earnings Call Transcript | N/A |  |
| 2023-02-14 04:46 EST | News | Basilea Pharmaceutica AG GAAP EPS of CHF 1.02, revenue of CHF 147.8M; initiates FY22 guidance | N/A | |
| 2023-01-24 11:14 EST | News | Basilea sees preliminary FY22 operating profit above outlook | N/A | |
| 2023-01-11 18:39 EST | News | Basilea reports 2022 revenue of CHF 148 million | N/A | |
| 2022-12-28 07:38 EST | News | Basilea repays 2022 convertible bonds | N/A | |
| 2022-08-16 19:38 EST | News | Basilea Pharmaceutica AG GAAP EPS of -CHF1.03, revenue of CHF58.6M beats by CHF14.31M | N/A | |
| 2022-08-16 19:38 EST | News | Basilea Pharmaceutica AG 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-08-16 19:38 EST | News | Basilea Pharmaceutica AG (BPMUF) CEO David Veitch on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-02-19 05:24 EST | News | Basilea Pharmaceutica AG 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-02-15 16:47 EST | News | Basilea Pharmaceutica AG GAAP EPS of -CHF0.58, revenue of CHF148.1M | N/A | |
| 2022-02-15 16:47 EST | News | Basilea Pharmaceutica AG (BPMUF) CEO David Veitch on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-18 02:55 EST | News | Basilea Pharmaceutica AG (BPMUF) CEO David Veitch on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-18 02:55 EST | News | Basilea Pharmaceutica AG 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-02-19 06:38 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-16 21:49 EST | News | Basilea Pharmaceutica AG reports FY 2020 results | N/A | |
| 2021-02-16 21:49 EST | News | Basilea Pharmaceutica AG 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-02-16 21:49 EST | News | Basilea Pharmaceutica AG (BPMUF) CEO David Veitch on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2020-12-04 18:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-25 14:49 EST | News | Basilea files China application for antifungal isavuconazole submitted by Pfizer accepted for review | N/A | |
| 2020-11-07 19:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-15 04:52 EST | News | Basilea Pharmaceutica AG (BPMUF) Investor Presentation - Slideshow | N/A | |
| 2020-08-15 03:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:23 EST | News | Basilea Pharmaceutica AG 2020 Q2 - Results - Earnings Call Presentation | N/A | |
| 2020-08-13 08:21 EST | News | Basilea Pharmaceutica AG (BPMUF) CEO David Veitch on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-11 05:21 EST | News | Basilea Pharmaceutica AG reports 1H results | N/A | |
| 2020-08-06 16:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 23:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:28 EST | Financials | Company financials have been released. | Neutral | |
About Basilea Pharmaceutica AG (BPMUF):
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia in European and various non-European countries. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. The company was founded in 2000 and is headquartered in Basel, Switzerland.
General
- Name Basilea Pharmaceutica AG
- Symbol BPMUF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 157
- Fiscal Year EndDecember
- Web URLhttp://www.basilea.com
Valuation
- Trailing PE 187.96
- Price/Sales (Trailing 12 Mt.) 3.65
- Enterprise Value Revenue 4.61
- Enterprise Value EBITDA 59.09
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -12%
- Return on Assets -6%
- Earnings Per Share -$1.99
- Revenue Per Share $0
- Gross Profit 6.17 million
- Quarterly Earnings Growth -18.1%
Highlights
- Market Capitalization 547.47 million
- Book Value Per Share -$5.41
Share Statistics
- Shares Outstanding 10.8 million
- Shares Float 8.96 million
- % Held by Insiders 227%
- % Held by Institutions 30.23%
Technicals
- Beta 0.98
- 52 Week High $60.34
- 52 Week Low $36.95
- 50 Day Moving Average 55.79
- 200 Day Moving Average 56.5
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Basilea Pharmaceutica AG (BPMUF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Basilea Pharmaceutica AG (BPMUF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | -$1.42 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | -$1.37 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $0.48 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $35.6 million | $0.47 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $35.6 million | -$0.34 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $31.59 million | -$0.33 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $31.59 million | -$0.74 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $36.34 million | -$0.72 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $36.34 million | -$0.41 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $22.71 million | -$0.42 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $23.19 million | -$1.05 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $22.05 million | -$1.09 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $22.11 million | $0.05 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $15.88 million | $0.05 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $15.46 million | -$0.99 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $17.66 million | -$0.95 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $17.66 million | -$1.13 | $0.00 | |
| 2016-06-30 | 2016-09-30 | -$1.19 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | -$1.41 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$1.44 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$1.55 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | -$1.58 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$1.60 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$1.54 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$1.11 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$1.15 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | -$1.11 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$1.11 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | -$0.90 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.88 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.95 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.95 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | -$1.05 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$1.02 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$1.90 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$2.00 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$2.09 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$2.16 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$1.25 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$1.15 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $7.36 | $0.00 |
Basilea Pharmaceutica AG (BPMUF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Basilea Pharmaceutica AG (BPMUF) Chart:
Basilea Pharmaceutica AG (BPMUF) News:
Below you will find a list of latest news for Basilea Pharmaceutica AG (BPMUF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Basilea Pharmaceutica AG (BPMUF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Basilea Pharmaceutica AG (BPMUF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|